Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New lemborexant efficacy and safety data unveiled

Key clinical point: Lemborexant effectively treated both sleep onset and sleep maintenance variables in men and women with insomnia.

Major finding: In both sexes, subject-reported sleep onset latency was significantly reduced versus that of placebo for lemborexant 5 mg and lemborexant 10 mg during the first 7 days and end of month 1 (P less than .05 for all comparisons).

Study details: A pooled analysis of data from 1,693 subjects enrolled in SUNRISE-1 and SUNRISE-2.

Disclosures: The research was supported by Eisai. Dr. Moline is an employee of the company.


Moline M et al. Sleep 2019, Abstract 0368.